Vaxcyte reported that its experimental pneumococcal vaccine, VAX-31, met primary endpoints in the first of three Phase 3 trials, producing antibody effectiveness that matched Wall Street expectations by performing at levels comparable to Pfizer and Merck across nearly all bacterial strains. VAX-31 is designed to cover 31 serotypes linked to pneumococcal disease. In the trial, just over 3,500 adults age 50 and older were randomized to receive VAX-31, Pfizer’s Prevnar, or Merck’s Capvaxive. Investigators then measured immune responses against different strains, using the strength of antibodies as the key effectiveness proxy. The result sets up a direct competitive challenge in a high-value vaccine market where serotype breadth and immunogenicity benchmarks determine differentiation. If subsequent Phase 3 readouts confirm durability and real-world effectiveness, Vaxcyte could accelerate regulatory and commercial plans for a late-stage candidate built to outcompete incumbents on coverage. The near-term news for biotech professionals is the competitive timing: a first Phase 3 win is often the gating milestone that shifts partner and payer discussions, and Vaxcyte now has a stronger position to negotiate follow-on trial strategies and eventual label claims.